Dourmishev Lyubomir A, Guleva Dimitrina V, Miteva Ljubka G
Department of Dermatology and Venereology, Medical University-Sofia, Bulgaria.
Int J Inflam. 2016;2016:3523057. doi: 10.1155/2016/3523057. Epub 2016 Jan 18.
Intravenous immunoglobulins (IVIGs), a mixture of variable amounts of proteins (albumin, IgG, IgM, IgA, and IgE antibodies), as well as salt, sugar, solvents, and detergents, are successfully used to treat a variety of dermatological disorders. For decades, IVIGs have been administered for treatment of infectious diseases and immune deficiencies, since they contain natural antibodies that represent a first-line defense against pathogens. Today their indication has expanded, including the off-label therapy for a variety of autoimmune and inflammatory diseases. In dermatology, IVIGs are administered for treatment of different disorders at different therapeutic regimens, mostly with higher doses then those administered for treatment of infectious diseases. The aim of this prospective review is to highlight the indications, effectiveness, side effects, and perspectives of the systemic treatment with IVIGs for patients with severe, life-threatening, and resistant to conventional therapies autoimmune or inflammatory dermatoses.
静脉注射免疫球蛋白(IVIG)是多种蛋白质(白蛋白、IgG、IgM、IgA和IgE抗体)以及盐、糖、溶剂和洗涤剂的混合物,已成功用于治疗多种皮肤病。几十年来,IVIG一直用于治疗传染病和免疫缺陷,因为它们含有天然抗体,是抵御病原体的一线防御。如今,其适应症已经扩大,包括用于多种自身免疫性和炎症性疾病的标签外治疗。在皮肤科,IVIG以不同的治疗方案用于治疗不同的疾病,大多使用比治疗传染病更高的剂量。这篇前瞻性综述的目的是强调IVIG全身治疗对患有严重、危及生命且对传统疗法耐药的自身免疫性或炎症性皮肤病患者的适应症、有效性、副作用及前景。